{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:40Z","timestamp":1789614160338,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 22869"],"award-info":[{"award-number":["IG 22869"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104897","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:35:17Z","timestamp":1786404917000},"page":"104897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors"],"prefix":"10.1016","volume":"89","author":[{"given":"Ilenia","family":"Migliaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5047-5571","authenticated-orcid":false,"given":"Marta","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-4854","authenticated-orcid":false,"given":"Chiara","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-564X","authenticated-orcid":false,"given":"Cristina","family":"Guarducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0349-0781","authenticated-orcid":false,"given":"Francesca","family":"Galardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-3489","authenticated-orcid":false,"given":"Giulia","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-8658","authenticated-orcid":false,"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-2997","authenticated-orcid":false,"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104897_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104897_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-021-06390-6","article-title":"Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis","volume":"191","author":"Shiino","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104897_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121894","article-title":"The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy","volume":"11","author":"De Santo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104897_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.breast.2026.104897_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.breast.2026.104897_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104897_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.breast.2026.104897_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104897_bib9","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.breast.2026.104897_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.breast.2026.104897_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.breast.2026.104897_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.breast.2026.104897_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104897_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ctrv.2011.11.006","article-title":"Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies","volume":"38","author":"Amir","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104897_bib15","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstr\u00f6m","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104897_bib16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00404-018-4954-7","article-title":"Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer","volume":"299","author":"Stueber","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.breast.2026.104897_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113397","article-title":"Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: a case-control study","volume":"195","author":"Morganti","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104897_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1015388","article-title":"Clinical implication of low estrogen receptor (ER-low) expression in breast cancer","volume":"13","author":"Reinert","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.breast.2026.104897_bib19","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104897_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104897_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"Curtit","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104897_bib22","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.ejca.2014.08.014","article-title":"Breast cancer during follow-up and progression - a population based cohort on new cancers and changed biology","volume":"50","author":"Karlsson","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104897_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3244","article-title":"Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain","volume":"14","author":"Duchnowska","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104897_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104897_bib25","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104897_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102136","article-title":"CDK4\/6 inhibitors: a focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer","volume":"93","author":"Migliaccio","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104897_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104897_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105126","article-title":"Clinicopathological features and genomics of ER-positive\/HER2-negative breast cancer relapsing on adjuvant abemaciclib","volume":"10","author":"Corti","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104897_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102825","article-title":"Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review","volume":"130","author":"Gheysen","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104897_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173025","article-title":"Estrogen-receptor loss and ESR1 mutation in estrogen-receptor-positive metastatic breast cancer and the effect on overall survival","volume":"16","author":"Westenend","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104897_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic evolution of breast cancer metastasis and relapse","volume":"32","author":"Yates","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.breast.2026.104897_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104897_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00924","article-title":"Notch signaling pathway and endocrine resistance in breast cancer","volume":"11","author":"Bai","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.breast.2026.104897_bib34","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1158\/0008-5472.CAN-07-1476","article-title":"Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer","volume":"67","author":"Macaluso","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104897_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.18632\/oncotarget.1036","article-title":"pRb controls estrogen receptor alpha protein stability and activity","volume":"4","author":"Caligiuri","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104897_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030510","article-title":"Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors","volume":"20","author":"Lopez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104897_bib37","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.7150\/thno.29164","article-title":"Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and HER2-Negative breast cancer","volume":"8","author":"Liu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.breast.2026.104897_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174416","article-title":"Genomic alterations associated with estrogen receptor pathway activity in metastatic breast cancer have a differential impact on downstream ER signaling","volume":"15","author":"Angus","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104897_bib39","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2026.104897_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1210\/me.2002-0318","volume":"17","author":"Cui","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.breast.2026.104897_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0533-z","article-title":"Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression","volume":"17","author":"Raha","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104897_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040466","article-title":"Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer","volume":"7","author":"Stone","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104897_bib43","first-page":"2279","article-title":"Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression","volume":"55","author":"Ferguson","year":"1995","journal-title":"Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:33:02Z","timestamp":1789612382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S0960977626002079"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104897","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104897"}}